We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 8 for:    Dapansutrile
Previous Study | Return to List | Next Study

Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03595371
Recruitment Status : Recruiting
First Posted : July 23, 2018
Last Update Posted : July 6, 2021
Sponsor:
Collaborator:
Radboud University Medical Center
Information provided by (Responsible Party):
Olatec Therapeutics LLC

Tracking Information
First Submitted Date  ICMJE June 11, 2018
First Posted Date  ICMJE July 23, 2018
Last Update Posted Date July 6, 2021
Actual Study Start Date  ICMJE May 15, 2018
Estimated Primary Completion Date December 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 20, 2018)
Schnitzler's Syndrome Symptom Index [ Time Frame: Day 14 ]
Proportion of subjects with Grade 0 or 1 SchS symptoms at end of treatment. The Schnitzler's Syndrome Symptom Index (SchS Index) is a composite index incorporating the investigator global assessment of disease activity and levels of plasma CRP. The SchS Index is graded on a 0 - 3 scale with 0 being the best score and indicating "no symptoms of Schnitzler's syndrome" and 3 being the worst score and indicating "severe symptoms of Schnitzler's syndrome".
Original Primary Outcome Measures  ICMJE
 (submitted: July 11, 2018)
SchS Grading Index [ Time Frame: Day 14 ]
Proportion of subjects with Grade 0 or 1 SchS symptoms at end of treatment
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 11, 2018)
  • Physical Examination [ Time Frame: Day 14 ]
    A full or targeted physical examination of the patient's major body systems
  • Vital signs - pulse [ Time Frame: Day 14 ]
    Pulse will be recorded and analyzed for changes.
  • Vital signs - temperature [ Time Frame: Day 14 ]
    Body temperature will be recorded and analyzed for changes.
  • Vital signs - respirations [ Time Frame: Day 14 ]
    Respiration rate will be recorded and analyzed for changes.
  • Vital signs - blood pressure [ Time Frame: Day 14 ]
    Systolic and diastolic blood pressure will be recorded and analyzed for changes.
  • Safety laboratory measures - chemistry markers [ Time Frame: Day 14 ]
    Blood samples will be drawn and analyzed for chemistry blood markers.
  • Safety laboratory measures - hematology/complete blood count [ Time Frame: Day 14 ]
    Blood samples will be drawn and a complete blood count will be performed.
  • Safety laboratory measures - urinalysis [ Time Frame: Day 14 ]
    Urine samples will be collected and analyzed.
  • Adverse events [ Time Frame: Up to 42 days ]
    Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event.
  • Photographs of posterior torso [ Time Frame: Day 14 ]
    Photographs of posterior torso or other non-identifying areas of the body displaying urticarial rash.
  • Investigator Global Assessment of Disease Activity [ Time Frame: Later of Day 14 or symptom relapse (expected no later than Day 28) ]
    One general question the Investigator is asked to answer about the overall perceived status of the subject's symptoms.
  • Subject Global Assessment of Disease Activity [ Time Frame: Later of Day 14 or symptom relapse (expected no later than Day 28) ]
    Overall assessment of disease activity in response to the question: Please note on this scale (0=bad; 10=outstanding) how you are feeling.
  • Subject Skin Assessment [ Time Frame: Later of Day 14 or symptom relapse (expected no later than Day 28) ]
    Extent of urticaria on subject's body.
  • Time to relapse of SchS Symptoms after cessation of dapansutrile [ Time Frame: Later of Day 14 or symptom relapse (expected no later than Day 28) ]
    Time to the emergence of Grade 2 or higher SchS symptoms
  • Subject Global Evaluation of Treatment [ Time Frame: Later of Day 14 or symptom relapse (expected no later than Day 28) ]
    Two general questions the subject is asked to answer about the overall perceived quality of the investigational product.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: July 11, 2018)
Plasma concentrations of dapansutrile [ Time Frame: Later of Day 14 or symptom relapse (expected no later than Day 28) ]
Blood samples analyzed for levels of dapansutrile.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome
Official Title  ICMJE A Pilot, Open-Label, Phase 2, Single-Center, Repeat Dose, Proof- Of-Concept Safety, Pharmacodynamics and Efficacy Study of Orally Administered Dapansutrile Capsules in Subjects With Schnitzler's Syndrome
Brief Summary This is a pilot, open-label Phase 2, single-center, repeat dose, single cohort, proof-of-concept, safety, pharmacodynamics and efficacy study of dapansutrile capsules to be conducted in subjects with Schnitzler's syndrome (SchS) currently well controlled by anakinra therapy. At least 5 but no more than 10 subjects will be enrolled.
Detailed Description

Subjects who are currently taking and responsive to anakinra (Kineret®) for at least 6 weeks will be screened for eligibility at the Screening / Baseline (Day 1) visit. Following confirmation of eligibility, subjects will be enrolled, the first dose of dapansutrile will be administered at the clinical site and safety and efficacy assessments will be completed. Subjects will self-administer dapansutrile twice a day by mouth for 14 consecutive days. Subjects will continue their standard dose of anakinra for Days 1, 2 and 3 of the 14-day Treatment Period and will then cease taking anakinra. At the end of the 14-day Treatment Period subjects will remain off all medication for Schnitzler's syndrome and at the first signs of a relapse or worsening of SchS symptoms, subjects will visit the study clinic for the Symptom Onset visit (SOV) to determine with the Investigator when injections of anakinra should be resumed. In addition, subjects will return to the study clinic on Days 5, 9, 14, 15,16, 18 and 21 for follow-up visits1 and will be contacted by telephone on Day 42 (± 3 Days) for additional follow-up. The Day 15 (± 1 day), Day 16 (± 1 day) and Day 18 (± 1 day) visits will only occur if anakinra therapy has not yet been resumed.

Subjects will be given the option to remain in the Nijmegen area after the Day 14 visit and return to the study clinic for the Day 15, 16 and 18 follow-up visits. Alternatively, subjects will be given the option to have these visits conducted at their home by a trained study nurse.

Safety assessments will be conducted at each visit and subjects will capture the frequency and intensity of symptoms, including body temperature, using a paper diary. Safety and tolerability will be evaluated by monitoring the occurrence of adverse events (AEs) and changes in abbreviated physical examination findings, vital signs and clinical safety laboratory test results (chemistry, hematology and urinalysis) and inflammatory biomarkers. Clinical activity will be evaluated by: Subject Diary (completed daily), Subject Global Assessment of Disease Activity, Investigator Global Assessment of Disease Activity, and analysis of biomarkers of inflammation, including changes in C-reactive protein (CRP). Daily diary assessments will be captured starting at the Screening / Baseline (Day 1) visit and will continue until Symptom Onset visit or Day 21 visit (whichever occurs latest).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Schnitzler Syndrome
Intervention  ICMJE Drug: dapansutrile
500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
Other Name: OLT1177 capsules
Study Arms  ICMJE Experimental: dapansutrile capsules
Hard gelatin capsules containing 100 mg of dapansutrile (API)
Intervention: Drug: dapansutrile
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 11, 2018)
10
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 28, 2023
Estimated Primary Completion Date December 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male and female subjects 18 years old or older
  2. Prior diagnosis of Schnitzler's syndrome
  3. Presence of Schnitzler's syndrome that is well controlled by and responsive to anakinra for at least 6 weeks prior to the Screening/Baseline visit
  4. Grade 0 SchS symptoms at the Screening/Baseline visit
  5. Acceptable overall medical condition to be safely enrolled in and to complete the study (with specific regard to cardiovascular, renal and hepatic conditions) in the opinion of the Investigator
  6. Ability to provide written informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the Investigator, to understand and comply with all the requirements of the study as outlined in the protocol.

Exclusion Criteria:

  1. Pregnant, nursing or intent to become pregnant during the study
  2. Not responsive or well controlled by anakinra therapy for at least 6 weeks prior to the Screening/Baseline visit
  3. Use or planned use of any prohibited concomitant medications/therapies such as immunotherapies or corticosteroids during the study (until relapse and resumption of anakinra injections)
  4. Active infection within 3 days prior to the Screening/Baseline visit
  5. History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or antibodies to Hepatitis C Virus (HCV)
  6. Any other concomitant medical or psychiatric conditions, including alcohol or substance abuse, diseases or prior surgeries that in the opinion of the Investigator would impair the subject from safely participating in the trial and/or completing protocol requirements
  7. Enrollment in any trial and/or use of any investigational product or device within the immediate 30-day period prior to the Screening/Baseline visit
  8. Enrollment in any study previously sponsored by Olatec Therapeutics LLC, specifically Study OLT1177-01, Study OLT1177-02, Study OLT1177-03, Study OLT1177-04 or Study OLT1177-05
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Robert Barrow +1 833-652-8321 inquiries@olatec.com
Listed Location Countries  ICMJE Netherlands
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03595371
Other Study ID Numbers  ICMJE OLT1177-07
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Olatec Therapeutics LLC
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Olatec Therapeutics LLC
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Radboud University Medical Center
Investigators  ICMJE
Study Chair: Curt Scribner, MD Olatec Therapeutics LLC
PRS Account Olatec Therapeutics LLC
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP